Warren Buffett is worth $150B — but says ‘academics', ‘professionals' refuse to invest like him for 1 reason
Few professional investors have been in the game as long as Warren Buffett. The legendary investor has been successfully picking stocks since he was just 11 years old. Today, the 94-year-old is the ninth richest person in the world, worth an estimated $150 billion, according to Bloomberg.
Buffett's success was already apparent in 1985, when he made his first TV appearance in an interview with George Goodman. During the interview, Goodman inquired why Buffett's relatively simple yet highly effective approach to investing hadn't been adopted by others.
Rich, young Americans are ditching the stormy stock market — here are the alternative assets they're banking on instead
I'm 49 years old and have nothing saved for retirement — what should I do? Don't panic. Here are 5 of the easiest ways you can catch up (and fast)
Home prices in America could fly through the roof in 2025 — here's the big reason why and how to take full advantage (with as little as $10)
'Well, I think partly because it is so simple,' Buffett responded.
Here's why he believes neglecting the simple approach is the biggest mistake many professionals and academics make while investing.
Academics and professionals get bogged down with overanalyzing data simply because they have the skills and the data is available, Buffett told Goodman.
'As a friend of mine says, to a man with a hammer everything looks like a nail. And once you have these skills, you just are dying to utilize them in some way. But they aren't important,' he said.
Since the interview, the amount of data available to the average investor has exploded.
In fact, ordinary investors even have access to tools such as Quiver Quantitative, which shows the stocks members of Congress are buying or selling, Insider Tracking, which follows the trades of corporate insiders and SkyFi, which offers investors satellite imagery.
This niche data might be useful in some cases, but it can also overcomplicate your investment strategy. Instead, most investors should consider Buffett's relatively straightforward approach.
Read more: Jamie Dimon issues a warning about the US stock market — says prices are 'kind of inflated.' Crashproof your portfolio with these 3 rock-solid strategies
According to Buffett, investing isn't a complicated data science experiment but a relatively simple business deal.
'If I were being asked to participate in a business opportunity, would it make any difference to me whether I bought it on a Tuesday or a Saturday or an election year or something?,' he asked Goodman. 'It's not what a businessman thinks about in buying businesses. So why think about it when buying stocks? Because stocks are just pieces of businesses.'
To apply Buffett's bottom-up approach, consider the merits and fundamentals of the business underlying each stock. Take the time to understand what the company produces and how it makes money.
For instance, if Nvidia stock were on your radar, it might be a good idea to learn about their semiconductor business and how demand is impacted by the rise of artificial intelligence software. It could also be worth considering products in their pipeline, such as the Blackwell Superchip, and its potential impact on the business's future.
The next step would be to examine the company's fundamentals. A good product or service isn't necessarily a good investment if the company is struggling to generate profit or cash flow. A track record of safe and consistent dividend payments could suggest that the underlying business is healthy and lucrative enough to reward shareholders.
PepsiCo, for example, has consistently raised its quarterly dividends for 53 years.
The final step is valuation. As Buffett once said, 'Price is what you pay; value is what you get.'
In other words, even an excellent business isn't a good investment if you pay too much for it. With this in mind, consider valuation metrics such as the price-to-earnings (PE) ratio or price-to-free-cash-flow multiples to ensure you're getting a good deal.
Google's parent company, Alphabet, currently trades at a PE multiple of 20.5, which is noticeably lower than its peers, Meta and Amazon, which are currently trading at PE ratios of 28 and 35 respectively.
By focusing on relatively cheap companies with robust financials and great products, you too can implement Buffett's simple investing approach. No fancy data analysis necessary.
Is your savings account struggling to keep up with soaring grocery prices? Here's how 2 minutes can earn you 9X the US national average — with no monthly fees
This self-made $500M real estate mogul reveals his 'essential' US portfolio that he says Amazon 'can't hurt' — here's how everyday investors can copy his secret formula
These 5 money moves will boost you up America's net worth ladder in 2025 — and you can complete each step within minutes. Here's how
This article provides information only and should not be construed as advice. It is provided without warranty of any kind.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Bloomberg
an hour ago
- Bloomberg
Higher Oil Is Positive for US Dollar: 3-Minute MLIV
Guy Johnson, Kriti Gupta and Mark Cudmore break down today's key themes for analysts and investors on "Bloomberg: The Opening Trade." (Source: Bloomberg)


Business Insider
an hour ago
- Business Insider
Healthcare Sector Taps AI Boom via Intuitive Surgical Stock (ISRG)
When investors think of artificial intelligence (AI), names like Nvidia (NVDA), Palantir (PLTR), and Alphabet (GOOGL) typically come to mind. But AI's impact extends well beyond the traditional tech sector. A standout example is Intuitive Surgical (ISRG), the clear global leader in robotic surgery, now making significant strides in integrating AI into healthcare. The company's latest system, the da Vinci 5, incorporates AI capabilities that could unlock a powerful new and recurring revenue stream. Confident Investing Starts Here: Despite its leadership position, Intuitive Surgical's stock remains more than 15% below its all-time high, primarily due to competitive concerns, which may offer a compelling entry point for long-term investors. Given Intuitive Surgical's strong technological moat, I believe concerns about competition are overstated. The company's sustained innovation and market leadership position it well to remain a long-term winner. Fortifying the Moat: Unpacking Intuitive's Enduring Market Leadership Thanks to the widespread adoption of its flagship da Vinci system, Intuitive Surgical commands an estimated 60% share of the global robotic surgery market in 2024. Once a system is installed, the company benefits from a steady stream of recurring revenue through the sale of consumables such as surgical instruments. Additionally, hospitals often choose to upgrade their systems over time to stay aligned with the latest technology, further reinforcing this revenue model. In 2024, Intuitive Surgical generated $8.4 billion in revenue, marking a 17% year-over-year increas e—a testament to its ability to effectively monetize its platform. But beyond the strong financials, the company's intangible advantages significantly deepen its competitive moat. Over the past three decades, the da Vinci system has amassed an extensive base of real-world clinical data, contributing to better patient outcomes—something that is difficult, if not impossible, for competitors to replicate quickly. Moreover, Intuitive Surgical is deeply embedded in healthcare systems worldwide. Hospitals invest heavily in training surgical teams, adapting clinical protocols, and integrating the technology into their workflows. This creates substantial switching costs and a high degree of operational lock-in. Even if a competitor were to offer a lower-cost alternative, the economic and logistical barriers to switching remain a significant deterrent. The Dawn of Intelligent Surgical Augmentation Launched in early 2024, the da Vinci 5 introduces advanced AI capabilities that could further solidify Intuitive Surgical's dominance in the robotic surgery market. This latest system marks a significant shift—from basic surgical automation to intelligent surgical augmentation. According to the company, the da Vinci 5 delivers 10,000 times the computing power of previous models, enabling it to process complex data in real-time and provide intelligent, context-aware support to surgeons during procedures. This enhanced computing power allows the system to capture and analyze detailed intraoperative data, which can then be used to optimize surgical workflows, tool usage, and procedural techniques. Over time, this creates a powerful data-driven flywheel, continuously improving outcomes and efficiency in the operating room, deepening Intuitive Surgical's competitive edge. A Look at the Competitive Robotic Surgery Arena Admittedly, the competitive landscape in surgical robotics is becoming increasingly dynamic. Medtronic (MDT), a long-standing medtech leader, is preparing to launch its robotic-assisted surgery (RAS) system, Hugo, with FDA approval expected later this year. Hugo is positioned to compete in soft tissue procedures such as urology and gynecology, as well as spine surgery, and is expected to leverage AI as a key differentiator. Meanwhile, Johnson & Johnson (JNJ) is advancing its Ottava system through clinical trials, targeting procedures like gastric bypass and hiatal hernia repair, directly competing with da Vinci in the minimally invasive space. Ottava features four robotic arms integrated into a standard surgical table, a design that aims to improve workflow efficiency by reducing equipment footprint in the operating room. Additionally, Stryker's Mako system continues to gain traction in orthopedic procedures, including hip, knee, spine, and shoulder surgeries. While Intuitive Surgical remains the clear leader in robotic-assisted soft tissue surgery, these emerging systems reflect a broader push by competitors to gain ground across various surgical specialties. While Intuitive Surgical's 60% market share may face some erosion as competition intensifies, the robotic surgery market is both vast and expanding, providing ample room for multiple players to thrive. Importantly, Intuitive Surgical's first-mover advantage remains a significant asset, having established deep clinical integration and brand trust over the course of several decades. Crucially, the company is consistently profitable and continues to invest heavily in research and development, reinforcing its ability to innovate and stay ahead of emerging competitors. These factors should help Intuitive Surgical sustain its leadership position even as the market evolves. Is Intuitive Surgical a Good Stock to Buy? On Wall Street, ISRG earns a Strong Buy consensus rating based on 18 Buy, two Hold, and one Sell ratings in the past three months. ISRG's average price target of $596.35 implies a 14.15% upside potential over the next twelve months. Earlier this week, William Blair analyst Brandon Vazquez maintained a Buy rating on ISRG. He addressed concerns over the emergence of third-party remanufactured instruments, which could threaten the company's highly profitable and recurring instruments and accessories segment. The analyst 'believes that the limited availability of FDA-cleared remanufactured instruments and the absence of third-party verification participation will likely restrict their widespread adoption. Vazquez also notes that hospitals may be hesitant to operate outside Intuitive Surgical's ecosystem due to the high costs and risks associated with robotics programs.' A Long-Term Bet on Surgical AI's Future The launch of the da Vinci 5 marks Intuitive Surgical's formal entry into the AI space, reinforcing its position at the forefront of the evolving robotic surgery market, even as competition intensifies. That said, several risks extend beyond the competitive landscape. Despite its recent pullback, Intuitive Surgical remains richly valued, trading at a P/E ratio of 77.2, which is well above that of its industry peers, leaving limited margin for error. The company also faces external pressures, including tariffs (estimated to impact about 1.7% of revenue) and the complexities of global expansion. Additionally, it is exposed to broader healthcare and regulatory shifts, such as the potential decline in bariatric surgery volumes resulting from the increasing use of GLP-1 medications. As AI becomes more central to its platform, data privacy concerns may also present regulatory and reputational challenges. Ultimately, Intuitive Surgical's strong market leadership and early integration of AI in a large, rapidly evolving industry give me confidence in the company's long-term potential, despite the presence of near-term risks and challenges.


Bloomberg
an hour ago
- Bloomberg
The China Show 6/13/2025
'Bloomberg: The China Show' is your definitive source for news and analysis on the world's second-biggest economy. From politics and policy to tech and trends, David Ingles and Avril Hong give global investors unique insight, delivering in-depth discussions with the newsmakers who matter. (Source: Bloomberg)